Although it is rare, knowledge of this risk is important both for the ophthalmologists who treat it and for the oncologists prescribing the anti-cancer treatment, say Michigan Medicine researchers. The cases of three recent patients, published in JAMA Ophthalmology, highlight the issue. Patients receiving immune checkpoint inhibitors developed uveal effusions and eye inflammation that affected their vision.
MENU
